48th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130315953 | GENERIC ASSAYS FOR DETECTION OF MAMALIAN REOVIRUS - The invention relates to generic methods for the detection and quantification of mammalian reoviruses. These may uses a reverse transcription (RT-PCR) real time (q-PCR) assay which amplifies a conserved region within all MRV types. The assays allow the quantification of MRV RNA molecules, irrespective of the particular virus type (e.g. MRV-1, MRV-2). The methods are particularly applicable in the monitoring of vaccine production processes. | 2013-11-28 |
20130315954 | METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS - The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein. | 2013-11-28 |
20130315955 | STABILITY AND POTENCY OF HEMAGGLUTININ - The present invention relates to methods of improving the stability and maintaining the potency of recombinant hemagglutinin formulations, in particular, recombinant influenza hemagglutinin (rHA). In particular, Applicants have shown that the stability of rHA formulations may be significantly improved by mutating cysteine residues or by formulating with a reducing agent and sodium citrate. | 2013-11-28 |
20130315956 | NEWCASTLE DISEASE VIRUS AND THE USE THEREOF AS A VACCINE - The present invention relates to a new Newcastle disease viruses of any genotype and novel fragments of the Newcastle disease virus genome encoding for the F and HN proteins constructed by reverse genetics and recombination, highly antigenic, for preparing vaccines for the prevention of the Newcastle disease by reducing viral shedding or for using as vectors with other viruses, lyophilized or in oil emulsion. Likewise, it can be used as vector in combination with other pathogenic agents. | 2013-11-28 |
20130315957 | METHOD OF TREATING VERTIGO - The invention is a method for reducing the symptoms of vertigo. The method is performed by delivering a therapeutically effective amount of presynaptic neurotoxin, such as Botulinum Toxin A, in a pharmaceutically safe form to suitable locations around the head and neck. | 2013-11-28 |
20130315958 | PNEUMOCOCCAL SEROTYPES - Disclosed is a new and emerging serotype of | 2013-11-28 |
20130315959 | COMPOUNDS - The invention provides a synthetic | 2013-11-28 |
20130315960 | CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation. | 2013-11-28 |
20130315961 | GENERATION OF NOVEL BONE FORMING CELLS (MONOOSTEOPHILS) FROM LL-37 TREATED MONOCYTES - In one embodiment, a monocyte derived bone-forming cell population is provided. In one embodiment, the cell population comprises an isolated monocyte cell population treated with an effective dose of LL-37. In another embodiment, a method of producing a population of monocyte-derived bone-forming cells is provided. The method comprises obtaining a blood sample from a subject; isolating a population of monocytes from the blood sample; treating the isolated monocytes with an effective dose of LL-37; and culturing the LL-37 treated monocytes until they differentiate into the population of monocyte-derived bone-forming cells. In another embodiment, a method of treatment for a bone injury or bone disease is provided. The method comprises administering a therapeutically effective amount of a composition to a subject having the bone injury or disease, the composition comprising a population of monoosteophils. | 2013-11-28 |
20130315962 | METHOD FOR STEM CELL DIFFERENTIATION IN VIVO BY DELIVERY OF MORPHOGENES WITH MESOPOROUS SILICA AND CORRESPONDING PHARMCEUTICAL ACTIVE INGREDIENTS - A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells. | 2013-11-28 |
20130315963 | Mechanically Strong Absorbable Polymeric Blend Compositions of Precisely Controllable Absorption Rates, Processing Methods, And Products Therefrom - Novel absorbable polymer blends are disclosed. The blends are useful for manufacturing medical devices having engineered degradation and breaking strength retention in vivo. The blends consist of a first absorbable polymeric component and a second absorbable polymeric component. The weight average molecular weight of the first polymeric component is higher than the weight average molecular weight of the second polymeric component. At least at least one of said components is at least partially end-capped by a carboxylic acid group. Further aspects are medical devices made therefrom. | 2013-11-28 |
20130315964 | PHARMACEUTICAL COMPOSITION AND METHOD OF INHIBITING OF PRODUCTION OR AMPLIFYING OF ELIMINATION OF P24 PROTEIN - The present invention relates to a pharmaceutical composition, comprising an activated-potentiated form of an antibody to CD4 receptor, and method of inhibiting of production or amplifying of elimination of P24 protein. | 2013-11-28 |
20130315965 | HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH - The present invention provides compositions comprising a compound of Formula I, and salts, hydrates, and isomers thereof. Methods of promoting bone growth, treating renal disease, and treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I, are also provided. Medical devices comprising compound of Formula I are also provided. | 2013-11-28 |
20130315966 | Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine Composition - The disclosure provides a method of preparing an immunologically-active adjuvant-bound freeze dried vaccine composition. A specific embodiment provides a stable vaccine composition comprising an aluminum-salt adjuvant, a recombinant | 2013-11-28 |
20130315967 | ANTAGONISTIC PROPERTIES OF REEF FISH MICROFLORA - The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom. | 2013-11-28 |
20130315968 | OMEGA-3 DIGLYCERIDE EMULSIONS - The present invention relates to omega-3 diglyceride emulsions characterized in that the lipid phase comprises at least about 40 wt.-% of diglycerides. Preferably about 70 wt.-% of the acyl-groups of said diglycerides, are eicoapentaenoic acid (EPA) groups and/or docasahexaenoic (DHA) groups. The invention further relates to methods of treatment using the omega-3 diglyceride emulsions. | 2013-11-28 |
20130315969 | Medicament and System for the Percutaneous Preparation of Medicaments - The invention relates to an application system provided with a micro emulsion ( | 2013-11-28 |
20130315970 | Systems and Methods for Inhibiting Formation of Stretch Marks - According to the invention, a method for inhibiting the formation of stretch marks is disclosed. The method may include applying an oil to a portion of a person's body. The method may also include placing a non-absorbent film over the oil on the portion of the person's body. The method may further include securing the non-absorbent film to the person's body. | 2013-11-28 |
20130315971 | SNOUT BEETLE ATTRACTANT - An odorant substance for use in as an attractant for snout beetles and a method for controlling snout beetles are provided. The odorant substance includes at least one of: Cyclopropane carboxylic acid; 5-Methyl-2-hexanone; 2,5-Dimethyl-4-methoxy-3(2H)-furanone (“Mesifurane or berry furanone”); Anisole; and 3-Methoxy acetophenone. The method of controlling snout beetles includes applying the odorant substance to attract the snout beetles, e.g. by applying the substance to mechanical traps, combining the substances with insecticides, or the like. | 2013-11-28 |
20130315972 | COMPOSITIONS AND METHODS FOR ANTIMICROBIAL METAL NANOPARTICLES - Compositions having antimicrobial activity contain particles comprising at least one inorganic copper salt; and at least one functionalizing agent in contact with the particles, the functionalizing agent stabilizing the particle in a carrier such that an antimicrobially effective amount of ions are released into the environment of a microbe. The average size of the particles ranges from about 1000 nm to about 3 nm. Preferred copper salts include copper iodide, copper bromide and copper chloride, most preferred being copper iodide. Preferred functionalizing agents comprise materials with a molecular weight of 60 or above, which include amino acids, other acidic materials, thiols, hydrophilic polymers, emulsions of hydrophobic polymers and surfactants. The functionalized particles are preferably made by a grinding process. | 2013-11-28 |
20130315973 | BIOCOMPATIBLE DEVICES COATED WITH A TRIBONECTIN AND METHODS FOR THEIR PRODUCTION - The present invention features biocompatible devices having a surface thereof coated with a composition that includes a tribonectin, and methods of making the devices. The tribonectin may, e.g., reduce microbial growth on or attachment to the surface of the biocompatible device. | 2013-11-28 |
20130315974 | Non-Hormonal Female Contraceptive - Disclosed herein are compositions and methods for controlling fertility of a female subject. Particularly exemplified are compositions comprising sugar derivatives, such as 2-deoxyglucose, D-mannoheptulose; and/or 5-thio-D-glucose. Also disclosed herein are methods of preserving ova supply in a female subject that involves administering glucose derivatives. The composition typically includes a glucose derivative that affects Foxo3a expression. | 2013-11-28 |
20130315975 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR - The invention relates to new keratinocytes which may be cultured in vitro and the use thereof for preparing a product which can be used to treat acute and chronic wounds, in combination with a DPP-4 inhibitor. | 2013-11-28 |
20130315976 | PATCH PREPARATION - The problem of the present invention is to provide a patch preparation containing a drug (excluding 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine and a physiologically acceptable acid addition salt thereof), which is superior in both the skin permeability of a drug, and adhesiveness in the presence of water. | 2013-11-28 |
20130315977 | TRANSDERMAL PATCH - The present invention relates to an external preparation for transdermal administration, which remarkably enhances the skin permeability of 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (compound A). The adhesive preparation of the present invention has an adhesive layer formed on one surface of a support, and the adhesive layer contains (i) compound A or a physiologically acceptable acid addition salt thereof, (ii) an adhesive, (iii) lactic acid, and (iv) an additive containing a particular permeation enhancer, whereby remarkably superior skin permeability is provided. | 2013-11-28 |
20130315978 | PATCH AND PATCH PREPARATION - The invention provides a patch and a patch preparation having an adhesive layer with a high adhesive force, wherein the hydrophobic adhesive layer does not bloom even when an organic fluid component having high polarity is contained therein. The patch contains a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a synthetic rubber having a viscosity average molecular weight of 1,700,000-6,500,000, an organic fluid component having high polarity, a tackifier, and magnesium aluminometasilicate. In the patch preparation, the above-mentioned adhesive layer further contains a drug. | 2013-11-28 |
20130315979 | Glucan Gels - The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 | 2013-11-28 |
20130315980 | CYCLODEXTRIN-BASED MATERIALS, COMPOSITIONS AND USES RELATED THERETO - This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials that release such active agents under controlled conditions. The invention also discloses compositions of cyclodextrin-modified polymer carriers that are coupled to biorecognition molecules for assisting the delivery of drugs to their site of action. | 2013-11-28 |
20130315981 | METHOD FOR INDUCING FAT LOSS IN MAMMALS - The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal. | 2013-11-28 |
20130315982 | LIPOSOMAL DRUG COMPOSITION CONTAINING A POLYMERIC GUANIDINE DERIVATIVE - A liposomal drug composition comprising: a dimeric or polymeric guanidine derivative or a pharmaceutically acceptable salt thereof as drug substance, and a lipid modified by polyethylene glycole (PEG). The drug composition have cytostatic and antimicrobial activity. | 2013-11-28 |
20130315983 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - The invention provides compositions with low toxicity and high bioavailability for treating cancer or for inhibiting the development of cancer | 2013-11-28 |
20130315984 | ANTI-TRYPANOSOMAL PEPTIDES AND USES THEREOF - The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides. | 2013-11-28 |
20130315985 | PROCESS FOR PREPARING PURIFIED NUCLEIC ACID AND THE USE THEREOF - The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether) | 2013-11-28 |
20130315986 | Tumor-Specific Delivery of Therapeutic Agents Via Liposomase - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with | 2013-11-28 |
20130315987 | LYOPHILIZED LIPOSOME COMPOSITION ENCAPSULATING A WATER-SOLUBLE DRUG AND PREPARATION PROCESS THEREOF - Disclosed is a lyophilized liposome composition encapsulating a water-soluble drug and a preparation process thereof. The lyophilized liposome composition comprises a water-soluble drug, a phospholipid, a polyethylene glycol-derivatized phospholipid, cholesterol and a lyoprotectant, wherein the lyoprotectant comprises a saccharide and a cyclodextrin or cyclodextrin derivative. The encapsulation rate of the lyophilized liposome composition encapsulating the water-soluble drug is ≧90%. | 2013-11-28 |
20130315988 | Pharmaceutical Composition - A composition comprising rifaximin in the form of particles, wherein substantially all the particles have a particle size less than or equal to 2 micrometres. | 2013-11-28 |
20130315989 | METHOD FOR TREATING A PATIENT VIA PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE - A composition for photodynamic therapy including a polymer capsule having a diameter of about | 2013-11-28 |
20130315990 | DISIALYLLACTO-N-TETRAOSE (DSLNT) OR VARIANTS, ISOMERS, ANALOGS AND DERIVATIVES THEREOF TO PREVENT OR INHIBIT BOWEL DISEASE - The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof. | 2013-11-28 |
20130315991 | GASTRO-RETENTIVE DRUG DELIVERY SYSTEM FOR CONTROLLED DRUG RELEASE IN THE STOMACH AND INTO THE UPPER INTESTINES - A gastro-retentive drug delivery system for controlled release of drugs in the stomach or upper gastro-intestinal track provides one or more polymers that hydrate and swell to immobilize the drug in situ in a protective, degradable envelope or cocoon. In one embodiment, oppositely charged polyelectroytes are admixed with the drug and filled in a capsule having a dissolution profile in stomach acid at body temperature. The dissolution profile of the capsule promotes formation of a poyelectrolyte gel complex. The gel complex increases retention time of the drug and reduces dosing requirements, increases absorption, reduces dose-dependent side effects, and provides reproducible, time-controlled drug residence in the GI tract. | 2013-11-28 |
20130315992 | PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE - The invention relates to compounds of general formula (I): wherein: each of R | 2013-11-28 |
20130315993 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release. | 2013-11-28 |
20130315994 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT - The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them. | 2013-11-28 |
20130315995 | DIRECT COMPRESSION POLYMER TABLET CORE - The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 80% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating. | 2013-11-28 |
20130315996 | BIO-FUNCTIONALIZED STIMULUS-RESPONSIVE DISSOLVABLE PEG-HYDROGELS - The present invention is directed to a bio-functionalized stimulus-responsive dissolvable PEG-hydrogel. This inventive stimulus-responsive dissolvable PEG-hydrogel comprises a matrix of PEG-polymers, which are modified to contain at least one multifunctional fusion protein, the multifunctional fusion protein preferably comprising as components a substrate binding peptide (SBP), preferably a repetitive RGD-binding peptide and/or a ZZ-binding domain, preferably a tag for purification, and at least one N- and/or C-terminal linker. The present invention is furthermore directed to the use of such inventive stimulus-responsive dissolvable PEG-hydrogels in the treatment of lesions, in surgical dressings, for wound treating, for soft and hard tissue regeneration, for the treatment of wounds in the oral cavity, in the field of ophthalmology, in the field of periodontal defects, etc. The invention also describes a method of treatment for such diseases. Additionally, the present invention provides a kit comprising the inventive stimulus-responsive dissolvable PEG-hydrogel and optionally further components. | 2013-11-28 |
20130315997 | Parenteral Composition Comprising Microspheres With a Diameter Between 10 And 20 Microns - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. | 2013-11-28 |
20130315998 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament. | 2013-11-28 |
20130315999 | COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING COMPOUNDFS FOR FOLLICULAR DELIVERY - The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. | 2013-11-28 |
20130316000 | COMPOSITIONS AND METHODS FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH 5-AMINOSALICYLATE - Embodiments are directed to compositions and related methods for treating gastrointestinal disorders with a granulated mesalamine formulation. In some embodiments, the gastrointestinal disorder being treated is irritable bowel syndrome (IBS). In some embodiments, the gastrointestinal disorder being treated is diarrhea-predominant IBS (d-IBS). | 2013-11-28 |
20130316001 | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS - Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye. | 2013-11-28 |
20130316002 | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL MOTILITY DYSFUNCTION - Extended release oral dosage forms for the treatment of gastrointestinal motility disorders are described. Active agents which are small molecules, peptides, peptide analogs, and peptide mimetics are formulated for optimal release in the GI tract of subjects with GI motility dysfunction. Methods of treatment using the dosage forms are also described. | 2013-11-28 |
20130316003 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The invention features a method of treating a subject in need of treatment for multiple sclerosis. The method involves orally administering to the subject in need thereof a pharmaceutical composition in unit dosage form consisting essentially of (a) from about 120 mg to about 240 mg of dimethylfumarate formulated for delayed release, and (b) one or more pharmaceutically acceptable excipients, wherein following the orally administering of the unit dosage form monomethylfumarate appears in the plasma of the subject upon hydrolysis of dimethylfumarate and the Cmax of the monomethylfumarate in the plasma of the subject is between about 0.4 and about 2 mg/L, and wherein about 480 mg of dimethylfumarate per day is orally administered to the subject. | 2013-11-28 |
20130316004 | COMPOSITIONS AND METHODS FOR STABILIZING SUSCEPTIBLE COMPOUNDS - Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. | 2013-11-28 |
20130316005 | COMBINATION AND COMPOSITION FOR TREATING OBESITY - The present invention relates to the pharmaceutical field, especially the field of combination and pharmaceutical compositions that comprise a lipase inhibitor and a phytoalexin and pharmaceutically acceptable vehicles or excipients; the present invention also relates to the method for manufacturing compositions containing the combination and the use of said composition in the treatment of conditions of excess weight, obesity and related health problems. | 2013-11-28 |
20130316006 | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS - Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye. | 2013-11-28 |
20130316007 | Microcapsule Preparation of Alginate-Chitosan Acyl Derviatives, Preparation and Application Thereof - The present invention relates to a microcapsule preparation product of alginate-chitosan acyl derivatives, which is produced by mixing microcapsules of alginate-chitosan acyl derivatives with an aqueous solution, wherein the biomicrocapsule structureconsists of two parts, a microcapsule membrane and an inner core; the microcapsule membrane is a polyelectrolyte composite hydrogel membrane formed by chitosan, alginates and chitosan acyl derivatives, and the inner core is an alginate liquid or a hydrogel environment containing cells. | 2013-11-28 |
20130316008 | MULTICOMPARTMENTALIZED VESICULAR STRUCTURE AND A METHOD FOR FORMING THE SAME - The present invention provides a method for forming a multicompartmentalized vesicular structure comprising an outer block copolymer vesicle and at least one inner block copolymer vesicle, wherein the at least one inner block copolymer vesicle is encapsulated inside the outer block copolymer vesicle. The method comprises forming the at least one inner block copolymer vesicle by any method and adding block copolymers dissolved in a suitable solvent to a dispersion of the at least one inner block copolymer vesicle in an aqueous buffer under conditions that allow the block copolymers to form the outer block copolymer vesicle and encapsulate the at least one inner block copolymer vesicle. A multicompartmentalized vesicular structure and its uses are also provided. | 2013-11-28 |
20130316009 | COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS - Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. | 2013-11-28 |
20130316010 | POLYMERIC MICROPARTICLES - A pharmaceutical composition is provided comprising microparticles encapsulating high weight percent active agent and providing sustained release over a prolonged period of time of active agent levels bioequivalent to direct administration of active agent. Polymeric microparticle compositions containing one or more active agents, and methods of making and using thereof, are described. The microparticles are optimized for the agent to be delivered, so that the hydrophobicity or hydrophilicity of the polymer and charge of the polymer maximizes loading of the agent, and the selection and molecular weight of the polymers maximize release of an effective amount of the active agent for the desired period of time. | 2013-11-28 |
20130316011 | Expanded Utility of Red Cell-Derived Microparticles (RMP) for Treatment of Bleeding - Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired. Administration of RMP prepared according to the invention demonstrates effectiveness in safely reducing bleeding. | 2013-11-28 |
20130316012 | Method of Demineralizing Bone - The invention is directed to an apparatus for producing demineralized osteoinductive bone. The apparatus demineralizes bone by subjecting bone, including, for example, ground bone, bone cubes, chips, strips, or essentially intact bone, to either a rapid high volume pulsatile acidification wave process or to a rapid continuous acid demineralization process. The pulsatile acidification wave process includes subjecting bone to two or more rapid pulse/drain cycles in which one or more demineralizing acids is rapidly pulsed into a vessel containing bone, and after a desired period of time, is rapidly drained from the vessel. The continuous acid demineralization process includes subjecting bone to a continuous exchange of demineralizing acid solution in which the demineralizing acid solution is recirculated from the container holding the bone through an ion exchange media. Calcium and phosphate are thereby removed from the bone to produce a regenerated acid, and the regenerated acid is returned to the container holding the bone. Both processes allow bone to be rapidly demineralized to a precise and specific desired residual calcium level without sacrificing osteoinductivity. | 2013-11-28 |
20130316013 | Compositions for Preventing Cardiac Arrhythmia - Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject. | 2013-11-28 |
20130316014 | METHODS FOR PREDICTING PROGNOSIS OF A SUBJECT WITH A MYELOID MALIGNANCY - One aspect of the present disclosure includes a method for predicting the prognosis of a subject with a myeloid malignancy. One step of the method includes obtaining a biological sample from the subject. Next, at least one mutation in a spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein that results in defective splicing can be detected in the biological sample. The presence of at least one mutation in the spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein, is indicative of the subject's prognosis. | 2013-11-28 |
20130316015 | Methods for Repairing Cartilage - The invention relates to compositions, dosage forms and methods for stimulating cartilage growth, regeneration or repair, and treating cartilage defects and diseases using short chain polyphosphates, in particular polyphosphates having a chain length of greater than 5 phosphate units. The compositions, dosage forms and methods have particular application in the treatment of osteoarthritis. | 2013-11-28 |
20130316016 | ANTIBACTERIAL OR ANTI-ACNE FORMULATIONS CONTAINING USNIC ACID OR AN USNATE AND A METAL SALT - An antibacterial or anti-acne formulation suitable for topical or local application to human skin containing (a) either usnic acid or an usnate and (b) a metal salt selected from copper salts, bismuth salts, and mixtures thereof, wherein if the component (a) is an usnate, the components (a) and (b) are not the same compound. | 2013-11-28 |
20130316017 | Oral Composition for the Treatment of Acne - Provided is a composition that is useful for treating acne, and which has been found to reduce and/or eliminate acne outbreaks or reduce the severity thereof. The composition includes mangosteen and curcumin. At least a portion of the mangosteen and curcumin can be provided in the form of extracts thereof. The composition can optionally include other components such as guggul, guggul extracts, thyme, thyme extracts, piperine, vitamin B5, vitamin B6, zinc, beta glucans, and green tea extracts. The composition can be provided as an oral administration unit such as a pill or capsule. Also provided is a method of treating acne by ingesting an effective amount of the composition described herein. | 2013-11-28 |
20130316018 | Manufacture process for the preparation of an iron containing phosphate adsorbent - The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties. | 2013-11-28 |
20130316019 | Production Process for a Stabilized Aqueous Solution of Oxidizing Chlorine and a Stabilized Aqueous Solution of Oxidizing Chlorine Produced in this Manner - A process is described for the preparation of a stabilized aqueous solution of oxidizing chlorine (anolyte). The process comprises electrolysis of an aqueous solution of sodium chloride or potassium chloride in an electrolytic cell having at least one anode compartment and one cathode compartment separated by a semi-permeable membrane to obtain an anolyte solution in the anode compartment and a catholyte solution in the cathode compartment, and the addition to the anolyte solution produced in this way of a stabilizing agent selected from the group consisting of hydrochloric acid (HCl) of 50 to 250 mg/l, sulphuric acid (H | 2013-11-28 |
20130316020 | WOUND DRESSINGS COMPRISING CHLORITE - This application described a wound dressing comprising an absorbent material, an effective amount of chlorite and an amount of a base to provide a pH of the dressing material greater than or equal to about ( | 2013-11-28 |
20130316021 | TREATMENT OF RESPIRATORY DISEASES - A method for treating a mammal suffering from a respiratory disease characterized by acute intermittent or chronic obstruction of the airways of the lungs, such as asthma, acute asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis comprising delivering to the lungs of the mammal a perfluorocarbon and a gas mixture comprising carbon dioxide (CO | 2013-11-28 |
20130316022 | METHOD TO ENHANCE ANTIMICROBIAL ACTIVITY BY INCREASING pH - The invention provides a method to enhance antimicrobial activity, e.g., in a mammal. | 2013-11-28 |
20130316023 | HOP OXIDATION-REACTION PRODUCT, PREPARING METHOD THEREOF AND USE THEREOF - The present invention relates to a food product and food additive comprising a hop oxidation-reaction product or an extract thereof, as well as to a fat accumulation suppressing agent and a weight gain suppressing agent having it as an active ingredient. | 2013-11-28 |
20130316024 | COSMETIC KIT AND USE FOR IMPROVING THE APPEARANCE OF THE SKIN - A cosmetic kit and the use thereof for improving the appearance of the skin is described. Further described, is the prevention and/or controlling of cellulite or the orange peel syndrome and/or for slimming down the figure, through the increase of the elasticity and firmness of the skin by stepping up collagen synthesis, for increasing blood microcirculation and for improving thermoregulation of the skin. | 2013-11-28 |
20130316025 | Cranberry Xyloglucan Oligosaccharide Composition - A composition prepared from a cranberry hull enzyme-treated composition which reduces or inhibits the adhesion of microorganisms to cells having α-Gal-(1-4)-Gal terminal oligosaccharide receptors for adhesion. | 2013-11-28 |
20130316026 | XYLITOL-BASED ANTI-MUCOSAL COMPOSITIONS AND RELATED METHODS AND COMPOSITIONS - Compositions and methods for alleviating an allergy condition while also reducing a drying effect of an allergy medication or another anti-mucosal composition. In some embodiments, a nasal solution for alleviating an allergy condition may comprise an anti-mucosal composition in an amount effective for treating an allergy condition and at least one of xylitol and xylose in an amount effective for reducing nasal dryness caused by the anti-mucosal composition. | 2013-11-28 |
20130316027 | ANTIMICROBIAL COMPOSITION - The invention relates to an antimicrobial composition. The invention more particularly relates to a composition comprising a combination of two materials that interact synergistically to provide virus kill in a short time. The present inventors have found that a combination of a cationic surfactant e.g. benzalkonium chloride and an extract of a rhizome viz. | 2013-11-28 |
20130316028 | FREEZE DRIED EXTRACT OF PARKIA, PREFERABLY OF PARKIA SPECIOSA BEANS FOR TREATMENT OF DISEASES SUCH AS DIABETES MELLITUS TYPE 2 - The invention relates to a process for the preparation of a freeze-dried fruit of | 2013-11-28 |
20130316029 | METHODS AND COMPOSITIONS SUITABLE FOR MANAGING BLOOD GLUCOSE IN ANIMALS - The invention provides methods, compositions, and dietary formulations useful for managing blood glucose, preventing or treating insulin resistance, and improving insulin sensitivity. The methods comprise administering to an animal a therapeutically effective amount of a combination of at least two of one or more antioxidants; one or more anti-glycation agents; one or more body fat reducing agents; one or more insulin sensitivity enhancing agents; and one or more anti-inflammatory agents. | 2013-11-28 |
20130316030 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING COMPLICATIONS OF DIABETES CONTAINING A TRADITIONAL ORIENTAL MEDICINE EXTRACT OR A FRACTION THEREOF AS AN ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetic complications comprising the extract of | 2013-11-28 |
20130316031 | MILK YIELD AND/OR MILK QUALITY IMPROVING AGENT, PERINATAL DISEASE PREVENTIVE OR THERAPEUTIC AGENT, AND REPRODUCTIVITY IMPROVING AGENT FOR RUMINANT - An object of the present invention is to improve the milk yield and/or milk quality of a ruminant for milk production, to prevent or treat a perinatal disease of a ruminant, and to improve the reproductivity of a ruminant. In order to solve the above-mentioned problem, the following is provided. An agent for improving at least one of milk yield and milk quality of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. An agent for preventing or treating a perinatal disease of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. An agent for improving reproductivity of a ruminant, comprising at least one of cashew nut shell liquid, heat-treated cashew nut shell liquid, anacardic acid, cardanol, and cardol. | 2013-11-28 |
20130316032 | SUBSTANCE FOR PREVENTING AND IMPROVING ARTHRITIS - This application provides a substance containing disrupted cells of an anti-inflammatory lactic acid bacterium and having an effect of preventing or improving arthritis in a subject, a composition containing the substance and the preparation method thereof, and a method for enhancing the effect of preventing and improving arthritis with the use of the substance. | 2013-11-28 |
20130316033 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN DERMATOLOGY - The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies. | 2013-11-28 |
20130316034 | Casting Machine Valve - The invention relates to a valve flap ( | 2013-11-28 |
20130316035 | PRESS MOLDING SYSTEM - A press molding system ( | 2013-11-28 |
20130316036 | Mold-Tool System Including Runner Assembly Configured to Provide Access Portal for Permitting Access to Assembly - A mold-tool system ( | 2013-11-28 |
20130316037 | Rotor Assembly with One-Piece Finger Member - A rotor assembly for extruding randomly shaped food items includes a one-piece finger member. The one-piece finger member reduces the downtime of the extruding machine containing the rotor assembly by reducing the number of parts in the rotor assembly and reducing the adjustment necessary after finger replacement. The proprietary threaded interface between the finger member and the improved extruder machine allows for quick swap out during extruder maintenance. | 2013-11-28 |
20130316038 | EPITAXIAL FORMATION SUPPORT STRUCTURES AND ASSOCIATED METHODS - Epitaxial formation support structures and associated methods of manufacturing epitaxial formation support structures and solid state lighting devices are disclosed herein. In several embodiments, a method of manufacturing an epitaxial formation support substrate can include forming an uncured support substrate that has a first side, a second side opposite the first side, and coefficient of thermal expansion substantially similar to N-type gallium nitride. The method can further include positioning the first side of the uncured support substrate on a first surface of a first reference plate and positioning a second surface of a second reference plate on the second side to form a stack. The first and second surfaces can include uniformly flat portions. The method can also include firing the stack to sinter the uncured support substrate. At least side of the support substrate can form a planar surface that is substantially uniformly flat. | 2013-11-28 |
20130316039 | Mold-Tool System Including Cooling-Insert Assembly being Positioned Proximate to Nozzle Assembly - A mold-tool system ( | 2013-11-28 |
20130316040 | Mold-Tool System Includes One-Piece Manifold Assembly having Each Inlet in Fluid Communication with Outlets - A mold-tool system ( | 2013-11-28 |
20130316041 | USE OF PROBIOTIC ORGANISMS SYNTHESIZING CAROTENOID COMPOUNDS TO ENHANCE HUMAN HEALTH AND NUTRITION - A method is disclosed for increasing systemic carotenoid levels in humans through oral consumption of tablets, capsules, food or beverage products containing organisms capable of synthesizing carotenoid compounds. Carotenoid synthesis may occur in situ by organisms colonizing the gut, or in food or beverage products where carotenoids accumulate and are subsequently consumed dietarily. The organisms may be either transgenic—thus expressing genes in the carotenoid synthesis pathway derived from other organisms, or they may comprise species or strains selected for natural synthesis of carotenoids. The central objective of the invention is to provide an improvement in human health through a novel method for supplying and delivering carotenoid compounds. | 2013-11-28 |
20130316042 | ENHANCED RELEASE OF LIPOPHILIC INGREDIENTS FROM CHEWING GUM WITH HYDROCOLLOIDS - Disclosed herein are chewing gum compositions comprising a pectin and a lipophilic ingredient. It has been found that the use of the pectin in a chewing gum composition provides for an enhanced release of the lipophilic ingredient, such as lipophilic flavor and lipophilic sensate compounds. | 2013-11-28 |
20130316043 | GLUCOSYLATED STEVIOL GLYCOSIDES AS A FLAVOR MODIFIER - A taste and flavor profile modifying composition is described. The composition includes glucosylated steviol glycosides which can modify the intensity of a taste and/or a flavor in a food or beverage product. | 2013-11-28 |
20130316044 | BREAD HAVING IMPROVED TEXTURE AND TASTE AND METHOD FOR PRODUCING SAME - The invention relates to bread having improved texture and taste and to the method for producing same, specifically to a bread obtained from wheat flour, having a reddish, crunchy crust, and prepared from pieces of precooked dough kept frozen until final baking, and to said pieces of precooked dough. The pieces of precooked dough are obtained from a dough that is a mixture of wheat flour, water, salt, liquid yeast and an improver comprising less than 5% of both hemicellulase and alpha-amylase, and of ascorbic acid and L-cysteine, by means of a method that includes kneading, resting, shaping, fermenting, cutting to form the slit, precooking and chilling. The precooked dough is preferably kept frozen until the bread is to be consumed, at which time it is baked at a temperature higher than usual for 2 minutes to 3 minutes 30 seconds. | 2013-11-28 |
20130316045 | PROCESS FOR THE MANUFACTURE OF CHEESE - The present invention relates to an improved process for the manufacture of cheese, in particular hard and semi-hard cheese types. There is provided a process for the manufacture of a natural cheese comprising the steps of inoculating milk with a bacterial starter culture, adding rennet to form a curd, and subjecting the curd to a salting step by the addition of salt wherein a hydrocolloid or mixture thereof is added to the curd during the salting step and the hydrocolloid or mixture thereof replaces at least part of the salt or is in addition to the salt used during the salting step. There is also provided the use of such a salt and hydrocolloid mixture as a process aid during the salting step of natural cheese production. | 2013-11-28 |
20130316046 | MILK-BASED ALTERNATIVE PRODUCT AND METHOD FOR PRODUCING THE SAME - The present invention concerns the production of a milk-based alternative product, using edible oil to substitute at least part of the milk fat. In particular, the present invention concerns the production of a cheese alternative product, an ice cream alternative product, a custard alternative product or a chilled or frozen dessert alternative product, using an edible oil to substitute at least part of the milk fat. Further, a milk based alternative product, in particular a cheese alternative product, an ice cream alternative product, a custard alternative product or a chilled or frozen dessert alternative product, and the use of an edible oil, in particular olive oil, for the production of the milk-based alternative product are disclosed. | 2013-11-28 |
20130316047 | PROCESS FOR THE PRODUCTION OF YEAST EXTRACTS HAVING LOW TURBIDITY - The present invention describes a process to produce a yeast extract comprising a) subjecting yeast to autolysis; and b) subjecting the autolysate to solid/liquid separation and recovering the soluble fraction, whereby the solid/liquid separation in step b) is done at a pH of less than 5.1. The process of the invention is simple, has a high yield, and results in a yeast extract having low turbidity. | 2013-11-28 |
20130316048 | COMPOSITIONS AND METHODS FOR REDUCING THE PATHOGEN CONTENT OF MEAT OR MEAT PRODUCTS - Compositions and methods useful for reducing or eliminating the presence of pathogens in meat or meat products are disclosed. Administration of one or more lactic acid producing microorganisms to a live animal, to a carcass, to meat, to meat products, or in animal feed results in significant reductions in the amount of pathogens potentially harmful to humans when ingested. Synergistic effects can be achieved with the administration of multiple strains of microorganisms. | 2013-11-28 |
20130316049 | Galactofructose for its regulating effect on intestinal transit - Galactofructose for its regulating effect on the intestinal transit time of mammals, when it is incorporated into a food composition and when said composition is absorbed by the mammal in an amount corresponding to daily doses of galactofructose, averaged over 30 days, of between 0.1 and 2 g. | 2013-11-28 |
20130316050 | NUTRIENT DELIVERY COMPOSITION - A nutrient delivery composition includes a nougat core having a volume and a nougat surface. A chewable coating surrounds the nougat core. One or more nutrients is located within the nougat core, intermediate between the surface and said chocolate coating, or within the coating. A kit for nutrient delivery includes at least two nutrient delivery compositions that vary in contained nutrients. Instructions for the consumption of the compositions on a regular basis to supply a subject with a palatable nutrition supplement are also provided. | 2013-11-28 |
20130316051 | APPARATUS AND PROCESS FOR HEAT TREATING A PACKAGED FOOD PRODUCT - The invention provides an apparatus (for heat treating a packaged food product), comprising (a) a channel surrounding a channel interior, (b) a pressurizer, (c) a transport unit, (d) a first electrode, surrounding at least part of the channel interior over a first electrode length, (e) an electrode configuration comprising (i) a second electrode surrounding at least part of the channel interior over a remote part surrounding length (for shielding at least part of the channel), and (f) a radio frequency wave generator configured to generate RF-waves between the first and second electrode. With such apparatus efficiently energy may be coupled into the packaged food product, for instance for heating a meal and/or for pasteurizing a food product. A further advantage of the present apparatus and such process is that it may be configured to be used in a continuous process. | 2013-11-28 |
20130316052 | METHOD TO SEPARATE LIPIDS FROM CHEESE WHEY AND FAT-FREE WHEY PROTEIN PRODUCT FORMED THEREBY - Disclosed is a method of selectively separating milk fat globule membrane fragments and milk fat globules from whey. The method includes the steps of adding to whey an amount of a whey-soluble zinc salt and adjusting the pH of the whey to be less than 6.0. The amount of zinc salt added to the whey is sufficient to cause milk fat globule membrane fragments and milk fat globules contained in the whey to precipitate selectively from the whey. | 2013-11-28 |